A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract

被引:0
作者
Mohamed S. Abdel-Hamid
Mahmoud Y. Issa
Ghada A. Otaify
Maha S. Zaki
机构
[1] National Research Centre,Medical Molecular Genetics Department, Human Genetics and Genome Research Division
[2] National Research Centre,Clinical Genetics Department, Human Genetics and Genome Research Division
来源
Metabolic Brain Disease | 2017年 / 32卷
关键词
Cerebrotendinous xanthomatosis; gene- cerebellar manifestations; Xanthomas; Cataract; Cholestanol;
D O I
暂无
中图分类号
学科分类号
摘要
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disorder caused by deficiency of the mitochondrial cytochrome P450 sterol 27-hydroxylase enzyme encoded by CYP27A1 gene. CTX is characterized by tendon xanthomas, juvenile cataracts and multiple progressive neurological symptoms. Here we report on the clinical and molecular findings of a 35-years old Egyptian patient with CTX without cataract. Parents were first cousins with family history of two deceased sibs with mild impaired cognitive functions and epilepsy without appearance of tendon xanthomas. Our proband had learning disabilities and developed seizures at 9 years old. Tendon xanthomata appeared at the age of 16 and his neurological symptoms remained stationary till 28 years followed by progressive cerebello-pyramidal signs, dementia and psychiatric disturbance. Cataract was not evident in our patient. Brain MRI showed the characteristic focal lesions appeared as xanthomas in cerebellum and occipital horns of lateral ventricles. Molecular study identified a novel homozygous frameshift mutation in CYP27A1 gene, c.1169delT (p.K391Rfs*17). Our study emphasizes the important role of early genetic testing in prevention of morbidity and mortality of the disease and proper counseling. Moreover, it shows that the absence of cataract should not rule out the diagnosis of CTX.
引用
收藏
页码:311 / 315
页数:4
相关论文
共 103 条
  • [1] Appaduri V(2015)Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes Mol Genet Metab 116 298-304
  • [2] DeBarber A(2013)Cerebrotendinous xanthomatosis Curr Opin Lipidol 24 283-287
  • [3] Chiang PW(2010)Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid CNS Spectr 15 231-236
  • [4] Patel SB(2016)Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood Orphanet J Rare Dis 11 41-1188
  • [5] Steiner RD(2016)Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports Metab Brain Dis 31 1185-571
  • [6] Tyler C(2013)Psychiatric manifestations in cerebrotendinous xanthomatosis Transl Psychiatry 3 563-117
  • [7] Bonnen PE(2015)Novel cerebrotendinous xanthomatosis mutation causes familial early dementia in Colombia Biomedica 35 114-1810
  • [8] Björkhem I(2005)Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype Am J Med Genet 139 1805-429
  • [9] Bonnot O(2012)Myoclonus and dystonia in cerebrotendinous xanthomatosis Mov Disord 27 421-1121
  • [10] Fraidakis MJ(2014)A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis J Inherit Metab Dis 37 179-223